INVOKANA PI PDF

Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an INVOKANA mg once daily who have an eGFR of 60 mL/min/ m2. INVOKANA® is now the only oral diabetes treatment approved to in the INVOKANA® U.S. full Prescribing Information (PI).3 The PI also.

Author: Dorr Dairn
Country: Belgium
Language: English (Spanish)
Genre: Automotive
Published (Last): 21 April 2006
Pages: 148
PDF File Size: 2.22 Mb
ePub File Size: 20.21 Mb
ISBN: 576-9-91343-942-2
Downloads: 38146
Price: Free* [*Free Regsitration Required]
Uploader: Fenrizilkree

TGA eBS – Product and Consumer Medicine Information

Drug and Dose Specifics. Although more often diagnosed in older women, osteoporosis can affect anyone but there are several lifestyle changes you can make to keep your bones in the best health possible. UGT enzyme inducers speed up removal of Invokana from the body and make it pu effective. In turn, you eliminate more glucose in your urine which lowers your blood sugar levels.

Diet and exercise are the first steps in managing the disease, followed by the addition of drug therapy with metformin. What Do You Need to Know? Patients should be instructed to follow the directions provided in the Medication Guide. The PBAC noted that post marketing and long term safety data for canagliflozin are not yet available, invvokana considered that the toxicity profile may differ in clinical practice from that observed in the trials.

Median time to complete resolution of neutropenia was 13 days range: The submission claimed that canagliflozin mg treatment resulted in a statistically significant larger reduction in mean HbA1c from baseline compared with sitagliptin. Monitor patients during infusion and if a serious reaction occurs, discontinue infusion.

The PBAC noted a substantially higher incidence of both male and female genital mycotic infections and osmotic diuresis related adverse events in the canagliflozin arms compared to sitagliptin. These hematomas may result in long-term or permanent paralysis. In clinical trials, one out of approximately patients experienced an anaphylactic reaction.

  KSIKA METODA CALLANA PDF

I Missed My Dose of Invokana.

Metformin Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or when used concomitantly with other glucose-lowering agents such as sulfonylureas or insulin or ethanol. Canagliflozin is not PBS-subsidised for use in combination with metformin and a sulfonylurea triple oral therapyas monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor gliptinthiazolidinedione glitazone or a glucagon-like peptide If needed, Janssen, the manufacturer of Invokana, may be able to offer cost assistance for Invokana if onvokana qualify.

RxEconsult | Home

Post-marketing cases of liver injury, including some fatalities, have been reported. Perform appropriate tests, if indicated, to confirm AI.

Nearly all reactions occurred during infusion or within 4 hours of completing an infusion. If your blood sugar control is not adequate, your doctor may decide a higher Invokana dose is needed but only if your kidney function is good enough for the higher dose.

Supplementary indirect comparisons of canagliflozin mg with dapagliflozin 10 mg were also presented:. Clinical Place for the Proposed Therapy Type 2 diabetes is a metabolic disorder characterised by hyperglycaemia resulting from resistance to the action of insulin, insufficient insulin secretion or both.

Canagliflozin, tablet, 100 mg and 300 mg, Invokana® – July 2013

ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Invokana works in the kidneys, so you should not use Invokana if you have severe kidney problems or are on kidney dialysis. Before you take Invokana or other medications containing canagliflozin, tell your doctor if you have a history of amputation, ppi damage, or peripheral vascular disease.

The submission proposed that the place in therapy of canagliflozin is as an alternative treatment option, with a different mechanism of action, to the currently available oral antidiabetic agents. The PBAC accepted that canagliflozin is non-inferior in regards to efficacy and safety with dapagliflozin but noted variability in adverse events and differences in mechanism of action that may impact utilisation.

  KOMNAS LANSIA PDF

Avoid co-administration with CYP2D6 invo,ana with a narrow oi index. Monotherapy — When diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.

Prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin. The third-party service providers, not Janssen, are responsible for the information and assistance provided under this program. Signs of low blood sugar include: See latest Centers for Disease Control guidelines and recommendations for tuberculosis testing in immunocompromised patients. Monitor invokanna with neutropenia for signs of infection.

Indication and Important Safety Information

The PBAC did not consider this claim to be reasonable, agreeing that infections could be more common in non-trial populations, and considered that the cost of managing infections related to treatment should be accounted for. Also, the FDA warned that patients taking canaglifozin should notify their doctor right away if they notice any new pain, tenderness, sores, ulcers, or infections infokana their legs or feet.

Infusion reactions can also occur with subsequent infusions. The safety profile in adolescents with plaque psoriasis through Week 60 was similar to that of adults with plaque psoriasis.

This information and assistance are made available as a convenience to patients, and there is no requirement that patients or HCPs use any Janssen product in exchange for this information or assistance.

Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use.